Relmada Therapeutics (RLMD) Misses Q1 EPS by 1c
Tweet
Share
E-mail
Get Alerts RLMD Hot Sheet
Join SI Premium – FREE
Relmada Therapeutics (NASDAQ: RLMD) reported Q1 EPS of ($0.22), $0.01 worse than the analyst estimate of ($0.21).
For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates
- JPMorgan Upgrades IBM (IBM) to Overweight
- SEACOR Marine acknowledges letter from shareholder Pointillist
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
